BioSpace News Archive

AA Pharma Inc. is recalling two lots of Elavil and Apotex Inc. is recalling one additional lot of APO-Amitriptyline 10 mg tablets due to the presence of NDMA, a nitrosamine impurity, above the acceptable limit.

As of January 1, 2022 , Essity’s business areas are Health & Medical, Consumer Goods and Professional Hygiene.

UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure and services to modernize care delivery and health management, today announced it will host its inaugural Analyst Day on Wednesday, March 23, 2022 and will broadcast from the New York Stock Exchange.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced an expanded offering of proprietary technologies to aid the development of antibody and multispecific therapeutic modalities.

SpotSee®, a global leader in condition-indicating solutions that protect life sciences products against damage and ensure supply chain integrity, has finalized its acquisition of the assets of Biosynergy, Inc., a manufacturer of medical devices primarily used to monitor the core temperature of red blood cells.

Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it is starting a “Compassionate Use Clinical Trial” for treatment of Parkinson’s disease.

Titan Medical Inc. announced that it has received payment from Medtronic plc after successfully achieving the final milestone under the development and license agreement announced on January 4, 2022.

Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure, today announced its activities at the upcoming, first ever Technology and Heart Failure Therapeutics conference (THT 2022), which is produced by the Cardiovascular Research Foundation (CRF) and will be held February 1-2 at the New York Marriott Marquis.

South Carolina’s Integrated Micro-Chromatography Systems, Inc. (IMCS), a leader in recombinant enzymes and micro-chromatography technologies, was awarded $1.8 million for Phase II of its Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health/ National Institute of General Medical Sciences (NIH/NIGMS).

Novel Entactogen NCE Series Enhances the Potential for Improved Treatment of Addiction.